Home Cart Sign in  
Chemical Structure| 1550008-55-3 Chemical Structure| 1550008-55-3

Structure of ML264
CAS No.: 1550008-55-3

Chemical Structure| 1550008-55-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ML264 is a potent and selective KLF5 inhibitor.

Synonyms: CID-51003603

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ML264

CAS No. :1550008-55-3
Formula : C17H21ClN2O4S
M.W : 384.88
SMILES Code : O=C(NCC(N(C)C(CC1)CCS1(=O)=O)=O)/C=C/C2=CC=CC(Cl)=C2
Synonyms :
CID-51003603
MDL No. :MFCD30187519
InChI Key :AJCDZIDKYKCOMZ-AATRIKPKSA-N
Pubchem ID :51003603

Safety of ML264

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of ML264

MAPK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SW620 cells 0.001 to 20 μM 24 hours SR18662 had the highest inhibitory effect on SW620 cells, with an IC50 value about one log unit lower than those for ML264 and SR15006 Mol Cancer Ther. 2019 Nov;18(11):1973-1984
HT29 cells 0.001 to 20 μM 24 hours SR18662 had the highest inhibitory effect on HT29 cells, with an IC50 value about one log unit lower than those for ML264 and SR15006 Mol Cancer Ther. 2019 Nov;18(11):1973-1984
HCT116 cells 10 μM 24, 48, and 72 hours SR18662 significantly inhibited cell proliferation and growth, more effective than ML264 or SR15006 Mol Cancer Ther. 2019 Nov;18(11):1973-1984
DLD-1 cells 10 μM 24, 48, and 72 hours SR18662 significantly inhibited cell proliferation and growth, more effective than ML264 or SR15006 Mol Cancer Ther. 2019 Nov;18(11):1973-1984
MDA-MB-468 10 μM 48 h Evaluate the effect of ML264 and its derivatives on MDA-MB-468 cell viability Theranostics. 2017 Jun 11;7(8):2339-2349
HCC1806 10 μM 48 h Evaluate the effect of ML264 and its derivatives on HCC1806 cell viability Theranostics. 2017 Jun 11;7(8):2339-2349
MDA-MB-231 10 μM 48 h Evaluate the effect of ML264 and its derivatives on MDA-MB-231 cell viability Theranostics. 2017 Jun 11;7(8):2339-2349
HCT116 10 μM 48 h Evaluate the effect of ML264 and its derivatives on HCT116 cell viability Theranostics. 2017 Jun 11;7(8):2339-2349
HEK293 cells 10 μM 24 hours ML264 reduced AA-induced Gpx4 promoter transcriptional suppression Redox Biol. 2023 Dec;68:102939
HK2 cells 10 μM 24 hours ML264 alleviated AA-induced abnormal expressions of GPX4 and 4-HNE, and reduced HDAC3 induction Redox Biol. 2023 Dec;68:102939
HK-2 cells 10 μmol/L 24 hours ML264 inhibits KLF5 activity, reduces phosphorylation of NF-κB p65, thereby decreasing NLRP3 inflammasome activation and pyroptosis. Cell Commun Signal. 2024 Mar 21;22(1):187
HCT116 cells 10µM 24, 48, and 72 hours ML264 significantly inhibited the proliferation of HCT116 cells, with a 15- to 30-fold reduction in live cell numbers after 72 hours. Mol Cancer Ther. 2016 Jan;15(1):72-83
DLD-1 cells 10µM 24, 48, and 72 hours ML264 significantly inhibited the proliferation of DLD-1 cells, with a 15- to 30-fold reduction in live cell numbers after 72 hours. Mol Cancer Ther. 2016 Jan;15(1):72-83
CRC PDOs 10 μM 7 days ML264 significantly restored oxaliplatin sensitivity in CRC PDOs by restoring the apoptotic response, and this effect was achieved by inhibiting the KLF5/Bcl-2/caspase3 signaling pathway. Cell Death Dis. 2022 Apr 5;13(4):303

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice APP/PS1 mice Intraperitoneal injection 5 mg/kg Every other day for 15 weeks To study the effect of ML264 on cognitive function and Aβ deposition in AD model mice, it was found that ML264 significantly improved cognitive deficits and reduced Aβ deposition. Alzheimers Res Ther. 2022 Jul 26;14(1):103
Nude mice DLD-1 human colorectal cancer xenograft model Intraperitoneal injection 10 mg/kg (once daily), 10 mg/kg (twice daily), and 25 mg/kg (twice daily) Once or twice daily for 10 days ML264 significantly inhibited the growth of DLD-1 xenograft tumors, with a 25 mg/kg twice daily dose showing significant tumor volume reduction as early as 5 days after treatment. Mol Cancer Ther. 2016 Jan;15(1):72-83
BALB/c nude mice CRC xenograft tumor model Intraperitoneal injection 25 mg/kg ML264, 5 mg/kg oxaliplatin Oxaliplatin once a week, ML264 twice a week, lasting for 14 days ML264 significantly inhibited tumor growth in xenograft tumors and restored oxaliplatin-induced tumor apoptosis. Cell Death Dis. 2022 Apr 5;13(4):303
BALB/c nude mice A2780-olaR xenograft model Intraperitoneal injection 10 mg/kg Every two days until the end of the experiment Evaluate the in vivo therapeutic effect of ML264 on PARPi-resistant ovarian cancer. Results showed that ML264 alone significantly inhibited tumor growth, and the effect was more pronounced when combined with olaparib. J Transl Med. 2025 Apr 30;23(1):492

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.60mL

0.52mL

0.26mL

12.99mL

2.60mL

1.30mL

25.98mL

5.20mL

2.60mL

References

 

Historical Records

Categories